NCT01525901View on ClinicalTrials.gov

Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 23, 2016

Study Completion Date

August 23, 2016

Conditions
22q13 Deletion SyndromePhelan-McDermid Syndrome
Interventions
DRUG

Insulin-Like Growth Factor-1 (IGF-1)

IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.

DRUG

Normal saline

Saline solution will be administered for three months subcutaneously.

Trial Locations (1)

10029

Seaver Austin Center, Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT01525901 - Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome) | Biotech Hunter | Biotech Hunter